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i.org/1remodeling. Their serum levels are strongly related with mortality in chronic systolic heart
failure (HF). The aim of this study was to study prognostic value of HGF in acute HF,
interaction with ejection fraction, renal function, and natriuretic peptides. We included 373
patients (age 76 – 10 years, left ventricular ejection fraction [LVEF] 46 – 14%, 48% men)
consecutively admitted for acute HF. Blood samples were obtained at admission. All pa-
tients were followed up until death or close of study (>1 year, median 371 days). HGF
concentrations were determined using a commercial enzyme-linked immunosorbent assay
(human HGF immunoassay). The predictive power of HGF was estimated by Cox
regression with calculation of Harrell C-statistic. HGF had a median of 1,942 pg/ml
(interquartile rank 1,354). According to HGF quartiles, mortality rates (per 1,000 patients/
year) were 98, 183, 375, and 393, respectively (p <0.001). In Cox regression analysis, HGF
(hazard ratio1SD[ 1.5, 95% confidence interval 1.1 to 2.1, p[ 0.002) and N-terminal pro
b-type natriuretic peptide (NT-proBNP; hazard ratio1SD[ 1.8, 95% confidence interval 1.2
to 2.6, p[ 0.002) were independent predictors of mortality. Interaction between HGF and
LVEF, origin, and renal function was nonsignificant. The addition of HGF improved the
predictive ability of the models (C-statistic 0.768 vs 0.741, p [ 0.016). HGF showed a
complementary value over NT-proBNP (p [ 0.001): mortality rate was 490 with both
above the median versus 72 with both below. In conclusion, in patients with acute HF,
serum HGF concentrations are elevated and identify patients at higher risk of mortality,
regardless of LVEF, ischemic origin, or renal function. HGF had independent and additive
information over NT-proBNP.  2016 Elsevier Inc. All rights reserved. (Am J Cardiol
2016;118:543e549)Hepatocyte growth factor (HGF) is a disulfide-linked
heterodimeric molecule comprising a 69-kDa kringle-
containing a chain and a 34-kDa b chain.1 The HGF sys-
tem (HGF and its receptor c-Met) has been found in various
tissues and integrates complex biologic processes.2 HGF has
been described as a potent mitogenic growth factor for he-
patocytes thought to be liver specific but also reported toMedicina Interna, Facultad de Medicina, Instituto de
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0.1016/j.amjcard.2016.05.048possess mitogenic, motogenic, morphogenic, and anti-
apoptotic activities in different cell types.3e5 Binding of
HGF to its receptor c-Met leads to the activation of a signal
cascade whose ultimate in vivo effects include organ
development, angiogenesis, and tissue regeneration.6e8
Plasma concentrations of HGF are increased in response
to the damage of the liver and kidney.9e11
In the setting of cardiovascular diseases, an increase of
HGF has been observed in hypertension, atherosclerosis,
acute myocardial infarction, and chronic heart failure
(HF).12e15 In patients with advanced HF and depressed left
ventricular ejection fraction (LVEF), HGF has been re-
ported to be predictive of cardiovascular and all-cause
mortality, especially in patients with ischemic HF.16e18
This is possibly because of that ischemia is a strong
inducer of HGF synthesis.19 However, the value of HGF
concentrations in the setting of acutely decompensated HF
has not been evaluated, and data in HF patients with pre-
served LVEF are scarce.18
Therefore, this study was aimed to analyze the prognostic
information yielded by serum HGF concentrations in pa-
tients admitted for acute HF and to evaluate the interactionwww.ajconline.org
Table 1
Baseline clinical characteristics according to vital status at the end of follow-up
Variable Total population
(N¼373)
Alive
(N¼279)
(74.8%)
Deaths
(N¼94)
(25.2%)
p
Age (years) 76.32 (10.02) 75.25 (10.37) 79.50 (8.17) <0.001
Male/Female 48.2%/51.8% 47.5%/52.5% 50.5%/49.5% 0.61
LVEF 46.43 (14.15) 47.05 (13.97) 44.51 (14.57) 0.14
LVEF >50% 51.1% 52.6% 46.6% 0.32
LA (mm) 47.31 (7.84) 46.62 (7.69) 49.77 (7.94) 0.007
LVMI (g/m2) 129.37 (46.39) 130.70 (45.97) 124.75 (48.12) 0.49
BMI (Kg/m2) 29.51 (5.55) 29.73 (5.76) 28.86 (4.84) 0.19
Atrial Fibrillation 51.5% 51.6% 51.1% 0.93
Hypertension 76.9% 76.7% 77.7% 0.85
IHD 36.7% 37.6% 34% 0.53
Valvular disease 39.2% 37.3% 45.5% 0.23
Diabetes mellitus 47.2% 45.2% 53.2% 0.17
Hyperlipidemia 43.3% 49.3% 26.1% 0.001
Stroke 16.3% 14.1% 23.2% 0.075
Peripheral vascular disease 10.9% 10.6% 12.2% 0.77
Hemoglobin (g/dL) 12.32 (2.16) 12.41 (2.15) 12.02 (2.15) 0.13
Uric acid (mg/dL) 7.71 (3.22) 7.53 (3.41) 8.31 (2.39) 0.32
Blood urea (mg/dL) 58.16 (47.42) 52.40 (42.99) 75.20 (55.42) <0.001
Creatinine (mg/dL) 1.45 (0.96) 1.39 (0.98) 1.61 (0.86) 0.06
Sodium (mEq/l) 138.88 (4.72) 139.15 (4.50) 138.08 (5.26) 0.057
Potassium (mEq/l) 4.25 (0.646) 4.21 (0.64) 4.36 (0.65) 0.044
Albumin < 3.5 g/dl 34.2% 30.3% 47.5% 0.015
Hyperlipidemia 36.7% 49.3% 26.1% 0.001
NT-proBNP* (pg/mL) 4233 (7133) 3556 (5461) 7489 (15077) <0.001
HGF* (pg/mL) 1942 (1354) 1759 (1262) 2299 (1439) <0.001
Cystatin* (mg/L) 1.45 (0.86) 1.37 (0.85) 1.67 (0.81) <0.001
eGFR MDRD (mL/min/1.72m2) 54.97 (24.54) 56.94 (24.79) 49.07 (22.89) 0.007
eGFR CKD-EPI (mL/min/1.72m2) 50.98 (21.70) 53.02 (21.70) 44.86 (20.59) 0.002
eGFR Hoek13
(mL/min/1.72m2)
52.22 (21.48) 54.99 (22.30) 43.85 (16.23) 0.000
BMI ¼ body mass index; eGFR¼ estimated glomerular filtration rate; eGFR CKD-EPI crea ¼ eGFR (CKD-EPI equation) based on Creatinine; eGFR CKD-
EPI cys ¼ eGFR (CKD-EPI equation) based on Cystatin C; eGFR Hoek13 ¼ eGFR (Hoek 13 equation) based on Cystatin C; HGF ¼ hepatocyte growth factor;
IHD ¼ ischemic heart disease; LA ¼ left atria; LVEF ¼ left ventricular ejection fraction; LVMI ¼ left ventricular mass index; MDRD ¼ eGFR by modified
diet renal disease formula; NT-proBNP ¼ amino terminal fragment of B type natriuretic peptide.
* Data are expressed as mean (SD) or median (IQR).
544 The American Journal of Cardiology (www.ajconline.org)with EF, HF origin, renal function, and natriuretic peptides
(NP).
Methods
From September 2009 to February 2013, we prospectively
recruited a total of 373 patients consecutively admitted with
acute HF. Local ethics committees approved the study, and
informed consent was obtained from each patient. Blood
sampleswere collected at admission and stored at80Cuntil
processed. Echocardiography was performed on all patients.
A final diagnosis of acute HF was established following the
criteria of contemporary guidelines.20 In addition to these
criteria, a concentration of N-terminal pro b-type natriuretic
peptide (NT-proBNP) >900 pg/ml at admission was an
inclusion criteria. Reference values from the N-terminal
Pro-BNP investigation of dyspnea in the emergency depart-
ment (PRIDE) study were followed.21 Patients with acute
coronary syndrome, significant valvular heart disease, chronic
obstructive pulmonary disease as source of dyspnea, pulmo-
nary embolism, ventricular arrhythmias, stage 5 chronickidney disease, liver cirrhosis, hyperthyroidism, Cushing’s
syndrome, and life expectancy <1 year were not included.
Clinical, echocardiographic, and biochemical characteristics
were prospectively recorded. Laboratory workup was per-
formed according to manufacturer instructions.
Blood samples for HGF measurement were centralized at
the immunology laboratory of one center. HGF concentra-
tions in human serum were determined by enzyme-linked
immunosorbent assay, according to manufacturer in-
structions (human HGF immunoassay, Quantikine ELISA;
R&D Systems Europe, Ltd, Abingdon, UK). The intra-assay
coefficient of variation for HGF was 7.1% for 339 pg/ml and
4.1% for 3,759 pg/ml. The interassay coefficient of variation
for HGF was 7.1% for 363 pg/ml and 5.4% for 3,790 pg/ml.
Glomerular filtration rate (GFR) was estimated through
several formulae: Modification of Diet in Renal Disease
Study equation, Chronic Kidney Disease Epidemiology
Collaboration equations based on creatinine, and Hoek
formula based on cystatin C.
During hospitalization, the physician responsible for
patients was unaware of HGF levels. Study end point was
Table 2
Characteristics of patients according to Hepatocyte Growth Factor quartiles
Q1
 1350
Mean  SD
Q2
1350-1900
Mean  SD
Q3
1901-2700
Mean  SD
Q4
 2700
Mean  SD
P
HGF (pg/mL) 1127 (226) 1642 (254) 2299 (313) 3466 (1699) <0.001
LVEF 45.72 (14.92) 45.81 (13.52) 48.26 (13.51) 45.55 (14.44) 0.56
LVEF >50% 49.4% 53% 58% 43.9% 0.32
LA (mm) 45.86 (9.42) 47.71 (8.96) 48.92 (6.71) 46.15 (6.45) 0.12
LVMI (g/m2) 151.17 (71.16) 129.18 (37.09) 124.15 (39.58) 125.79 (45.91) 0.17
Age (years) 74.19 (11.42) 76.38 (9.73) 77.32 (9.31) 77.06 (10.08) 0.18
Male/Female 60.7%/39.3% 50.6%/49.4% 43.5%/56.5% 42.4%/57.6% 0.06
BMI (Kg/m2) 29.02 (5.47) 28.70 (4.74) 29.81 (6.26) 30.52 (5.64) 0.14
Albumin < 3.5 mg/dL 25.6% 32.1% 43.5% 38.2% 0.11
Hemoglobin (g/dL) 12.43 (2) 12.43 (2.23) 12.14 (2.06) 12.15 (2.31) 0.69
Uric acid (mg/dL) 7.49 (4.70) 6.78 (1.59) 8.17 (2.48) 7.78 (2.48) 0.66
Sodium (mEq/L) 137.84 (4.63) 139.35 (4.55) 139.58 (4.45) 138.84 (5.19) 0.08
Potasium (mEq/L) 4.22 (0.58) 4.24 (0.70) 4.28 (0.55) 4.27 (0.70) 0.93
Blood urea (mg/dL) 48.58 (31.87) 56.18 (60.61) 56.17 (46.47) 69.29 (48.15) 0.04
Creatinine (mg/dL) 1.21 (0.38) 1.52 (1.51) 1.46 (0.81) 1.63 (0.87) 0.04
Atrial fibrillation 48.8% 58.8% 58.8% 38.8% 0.21
Hypertension 75% 72.9% 76.5% 82.4% 0.21
IHD 38.1% 35.3% 41.2% 37.6% 0.84
Valvular disease 34% 54.7% 40.6% 29.2% 0.16
Diabetes mellitus 41.7% 44.7% 49.4% 49.4% 0.25
Hyperlipidemia 47.9% 38.2% 51.8% 41.4% 0.78
Stroke 16.7% 17.9% 15.5% 17.2% 0.98
Peripheral vascular disease 5.9% 5.7% 22.5% 13.3% 0.12
eGFR MDRD (mL/min/1.72m2) 62.13 (21.82) 57.75 (29.04) 52.5 (22.96) 47.46 (22.36) 0.001
eGFR CKD-EPI (mL/min/1.72m2) 58.01 (19.80) 53.09 (23.26) 48.61 (20.84) 44.12 (20.97) <0.001
eGFR Hoek 13 (mL/min/1.72m2) 58.49 (23.45) 51.90 (19.39) 50.48 (21.48) 46.82 (18.94) 0.004
NT-proBNP* (pg/mL) 3195 (5041) 4513 (7079) 4661 (6715) 5408 (12346) 0.004
Cystatin C* (mg/L) 1.32 (0.59) 1.44 (0.82) 1.52 (1.07) 1.67 (0.90) 0.008
Loop diuretics 75.6% 83.1% 88.7% 90.5% 0.007
ACE inhibitors 62.7% 55.3% 46.9% 50.6% 0.016
ARB 24.1% 28.2% 30.9% 22.6% 0.8
MRA 45.5% 33.3% 50% 43.3% 0.9
BB 60.2% 57.6% 66.7% 57.1% 0.9
HGF concentration in pg/mL.
ACE ¼ angiotensin converting enzyme; ARB¼ angiotensin receptor blockers; BB ¼ beta-blockers; BMI ¼ body mass index; eGFR¼ estimated glomerular
filtration rate; eGFR CKD-EPI crea ¼ eGFR (CKD-EPI equation) based on Creatinine; eGFR CKD-EPI cys¼ eGFR (CKD-EPI equation) based on Cystatin C;
eGFR Hoek13¼ eGFR (Hoek 13 equation) based on Cystatin C; HGF ¼ hepatocyte growth factor; IHD¼ ischemic heart disease; LA¼ left atria; LVEF¼ left
ventricular ejection fraction; LVMI ¼ left ventricular mass index; MDRD ¼ eGFR by modified diet renal disease formula; MRA ¼ mineral receptor an-
tagonists; NT-proBNP ¼ amino terminal fragment of B type natriuretic peptide.
* Data are expressed as mean (SD) or median (IQR).
Heart Failure/HGF in Acute Heart Failure 545all-cause mortality. All patients were followed up until death
or close of study in August 2014 (371 days, range 2 to
1,782). Quantitative variables are described as mean values
(SD) or median values (interquartile rank). Qualitative
variables are shown as frequency distribution. For compar-
isons between quantitative variables, either Student’s t test,
ANOVA, or nonparametric Mann-Whitney or Kruskal-
Wallis tests were performed. For comparison of qualitative
variables, chi-square tests were used with evaluation of
linear trend in variables with ordered categories. Primary
variable of results was all-cause mortality. Mortality rates
are expressed as events per 1,000 patients-year. For com-
parison between mortality rates among HGF quartiles,
Kaplan-Meier and log-rank test were used. Additionally
Cox regression analysis was performed to estimate hazard
ratio (HR) and 95% confidence intervals (CIs) of mortality.
The main predictive variable was HGF levels. It wasstratified in 4 categories using quartiles as cut-off points and
then merged into 2 categories according to median value. By
orthogonal polynomials, it was found that the linear trend of
risk produced by HGF was significant; hence, it was also
examined as a quantitative variable. For this purpose, HGF
was standardized to a mean of 0 and SD of 1 to enable the
comparison of the size effect with NT-proBNP, which was
also standardized.
The independent predictive power of mortality associated
with HGF was performed with adjustment for potential
confounders. Model 1 included HFG concentration and age.
Model 2 included model 1 plus estimated GFR, hemoglobin,
albumin, diabetes, atrial fibrillation, and ischemic HF.
Model 3 included model 2 plus LVEF and NT-proBNP
concentrations. Model 4 included model 3 plus diuretic
doses and therapies for HF. In model 4, a sequential
exclusion was performed to evaluate independent predictors
Figure 1. Kaplan-Meier survival curves and mortality rates (1,000 patients/
year) according to HGF quartiles.
Table 3
Mortality risk associated with HGF concentrations (as per each SD increase
or above median) progressively adjusted for variables indicated in the
successive models
1 SD HGF HGF  1900
HR 95% CI p HR 95% CI p
Model 1 1.45 1.19-1.76 <0.001 2.46 1.54-3.92 <0.001
Model 2 1.46 1.08-1.99 0.015 2.83 1.42-5.68 0.003
Model 3 1.39 1.01-1.92 0.042 3.29 1.57-6.87 0.002
Model 4 1.55 1.10-2.18 0.013 3.36 1.49-7.55 0.003
Model 1: HFG concentration and age; Model 2: model 1 plus GFR,
hemoglobin, albumin, diabetes, atrial fibrillation and IHD; Model 3: model
2 plus LVEF and NT-proBNP concentrations; Model 4: model 3 plus
diuretic doses and evidence based therapies for HF.
Figure 2. Area under the curve for the discrimination of death: effect of
adding HGF to the best clinical model. Model 1 (black line): age, GFR,
hemoglobin, EF, treatment with loop diuretics and b blockers, diabetes,
atrial fibrillation, ischemic heart disease, and NT-proBNP. Model 2 (green
line): model 1 plus HGF concentrations.
546 The American Journal of Cardiology (www.ajconline.org)of mortality. The predictive ability of HGF was tested by
comparing the C Harrell statistical applied to variables
included in model 4 both with and without introduction of
HGF and by calculating the Integrated Discrimination
Improvement.
Finally, patients were classified into 4 categories ac-
cording to a combination of HGF and NT-proBNP values
above or below median: category 1: both below median;
category 2: only NT-proBNP above median; category 3:
only HGF above median; category 4: both above median. A
Kaplan-Meier analysis and a multivariate Cox regression
analysis were also conducted using this combined variable
to assess prognosis. Statistical results were consideredsignificant when the value of p was <0.05. Statistical pro-
cedures were performed with IBM Statistical Package for
the Social Sciences, version 20.0 (IBM Corp. Released
2011. IBM SPSS Statistics for Windows, Version 20.0.,
IBM Corp, Armonk, New York).Results
Three hundred seventy-three patients admitted to the
hospital with acute HF were recruited. Characteristics for
the population are presented in Table 1. Preserved ejection
fraction (LVEF 50%) represented 51% of patients. HGF
values were available for 338 of patients (90.6%). Patients
with missing values did not differ in any of the variables
analyzed (data not shown). Characteristics of patients ac-
cording to HGF quartiles are listed in Table 2. Concentra-
tions of HGF were associated with higher NT-proBNP and
cystatin C values and less satisfactory renal function values.
Mortality rates showed a significant and linear relation
with serum HGF quartiles (Figure 1). In univariate Cox
regression analysis and using Q1 as reference value, the in-
crease of risk between Q1 and Q2 was nonsignificant (HR
1.8, 95% CI 0.9 to 4, p ¼ 0.12), whereas the increase of risk
between Q1 and Q3 (HR 3.6, 95% CI 1.8 to 7.3, p <0.0001)
and between Q1 and Q4 (HR 3.8, 95% CI 1.8 to 7.7, p
<0.0001) were significant. Hence, HGF levels were regrou-
ped into 2 categories with a cut-off point in the median value
of distribution. In univariate analysis, HGF concentrations
above median increased mortality risk almost threefold (HR
2.7, 95% CI 1.7 to 4.3, p <0.0001). Furthermore, in quanti-
tative analysis, each elevation in 1 SD of HGF increased risk
of death by 47% (HR 1.47, 95% CI 1.2 to 1.78, p <0.0001).
The independent contribution of HGF to mortality risk in
the successive models considered is reflected in Table 3. In
Figure 3. Mortality rates and HR according to HGF and NT-proBNP serum concentrations above or below the median. “*,” Mortality rate is expressed per
1,000 patients/year). Data are expressed as HR and 95% CI.
Heart Failure/HGF in Acute Heart Failure 547Cox regression analysis, using a sequential exclusion pro-
cedure, only HGF (HR1SD ¼ 1.5, 95% CI 1.1 to 2.1, p ¼
0.002) and NT-proBNP (HR1SD ¼ 1.8, 95% CI 1.2 to 2.6,
p ¼ 0.002) were independent predictors for mortality. The
addition of HGF to the best predictive model significantly
improved predictive ability (Figure 2) and power of
discrimination (integrated discrimination improvement ¼
0.034, p ¼ 0.018).
Importantly, classification of patients into categories ac-
cording to NT-proBNP and HGF concentrations showed a
gradual increase in mortality rates (Figure 3). There were no
significant interactions between serum HGF and LVEF,
ischemic HF, estimated GFR, or NT-proBNP concentra-
tions, except for a nonsignificant trend observed for a better
predictive value of HGF in the presence of low NT-proBNP
concentrations (below median: HR1SD ¼ 1.76, 95% CI 1.2
to 2.5, p ¼ 0.002, vs above median: HR1SD ¼ 1.3, 95% CI
1.04 to 1.6, p ¼ 0.02) and preserved LVEF (preserved
LVEF: HR1SD ¼ 1.7, 95% CI 1.2 to 2.4, p ¼ 0.001 vs
reduced LVEF: HR1SD 1.36, 95% CI 1.1 to 1.7, p ¼ 0.008).
As shown in Figure 4, the risk of death increased acrossquartiles of HGF regardless of the presence of preserved or
reduced LVEF.
Discussion
Our results show that after an acute HF episode, serum
HGF concentrations are elevated and identify patients at
higher risk of all-cause mortality, regardless of LVEF status.
The information yielded by HGF serum concentration is
independent of clinical variables, including ischemic origin
and renal function. Interestingly, HGF showed an additive
effect with NT-proBNP, and the presence of high concen-
trations of both biomarkers significantly increased the risk
of death.
Several studies have found that serum HGF is elevated in
patients with HF and systolic dysfunction.15e17 A small
study in patients with acute HF showed that HGF is higher
at admission and gradually decreases during hospitaliza-
tion.15 Further studies have suggested that levels of HGF
correlate with severity and prognosis; Lamblin et al16 found
median HGF serum levels of 818 pg/ml in stable ambulatory
Figure 4. Mortality risk according to quartiles of serum concentration of
hepatocyte growth factor and the presence of preserved or reduced LVEF.
Q1 reference risk. Data are expressed as HR and 95% CI; p Value for global
interaction between HGF and EF, p ¼ 0.34. HFREF ¼ heart failure with
reduced ejection fraction.
548 The American Journal of Cardiology (www.ajconline.org)patients, whereas Rychli et al17 reported 2,460 pg/ml in
patients with advanced HF. Our study focused on patients
with acute HF at the time of admission and also found
elevated levels of HGF with a median of 1,942 pg/ml, which
is more than twice the concentration in ambulatory patients
and close to the values observed in patients with advanced
HF.16,17 As in the other studies, we also found a correlation
with NP concentrations and renal function measures but not
with LVEF, although the other studies did not include pa-
tients with preserved LVEF.15e17 This question is of interest
because our findings suggest that role of HGF is not limited
to systolic HF and HGF increased in a similar magnitude
irrespective of LVEF. The present study is the first to pro-
vide data supporting a prognostic value of HGF in 2 relevant
settings: acutely decompensated HF and patients with HF
with preserved LVEF. As in the other published stud-
ies,16e18 HGF emerged as a powerful and independent
prognosticator and identified patients at higher risk of death.
HGF concentrations and prognostic value were not influ-
enced by LVEF, and ischemic origin suggests that the
source of HGF is not influenced by systolic function or
origin. Although an increased RNA myocardial expression
of HGF and its receptor c-Met has been observed in animal
models of ischemia/reperfusion injury, an increased
expression has also been found in other organs such as
kidney, liver, and lung and also endothelial cells.22,23 Zhu
et al24 observed that levels of HGF in monocytes were
elevated and correlated with infarct size, suggesting that
inflammation is a determinant of enhanced production as a
response to organ injury. In acute HF, this defensive
response is present and correlates with severity, regardless
of LVEF. As a defensive response to organ damage, HGF
has anti-apoptotic, anti-fibrotic, and anti-inflammatory
properties and mediates regenerative and angiogenic ef-
fects actions recognized as beneficial in HF.3,5 Moreover, in
experimental models, the antagonism of HGF determinesorgan dysfunction, whereas stimulation or exogenous
administration improves survival and exerts organ
protection.23,25
We found a significantly linear correlation between
serum concentrations of cystatin C, NT-proBNP, HGF, and
mortality, as in previous studies.17,18 In the present study,
we found that both HGF and NT-proBNP provide com-
plementary information, namely that patients with both
biomarkers above the median had the highest risk of death,
suggesting the usefulness of this combination for refining
risk stratification in acute HF. Survival time shortened as
both HGF and NT-proBNP concentrations increased. This
complementary information may reflect what happens at a
cellular and organ level, not only in the myocardium but
also in other target organs given that HGF has a multiorgan
source. Nowadays, the pathophysiology of acute HF is un-
derstood as multiorgan damage in which congestion and
inflammation participate and determine a higher risk
phenotype.26
Although speculative, it is plausible to think that during
the acute phase of decompensation, both biomarkers reflect
complementary responses. The degree of HGF expression
and its association with prognosis reflects the degree of
disease. It would be similar to natriuretic peptides, which
represent a defensive response with biologic beneficial ef-
fects. It is in this context that increased levels of both bio-
markers should be interpreted—HGF and natriuretic
peptides reflect beneficial responses but, simultaneously, are
markers of severity. The potentiation of a hypothetical
beneficial physiological response may be of interest as a
therapeutic approach. Therefore, the additive value of HGF
and NP could be of additional interest, not only because
they are complementary in prognosis evaluation but also
because both responses could be synergistic from a thera-
peutic point of view.
The main limitations of this study are the observational
nature and the lack of serial measurements reflecting the
dynamics of an acute event. Nevertheless, the study pro-
vides meaningful information because it is the first to
evaluate the prognostic value of HGF at admission for acute
HF and also it provides information irrespective of LVEF.
The value of its combination with NP is novel and could
also serve as a basis for further research.Acknowledgment: The authors wish to thank to Michael
B. Smith for reviewing English version of the manuscript.
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